Overview

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults

Status:
Active, not recruiting
Trial end date:
2022-06-20
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy of AZD7442 for the post-exposure prophylaxis of COVID-19 in Adults.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborators:
Iqvia Pty Ltd
QuintilesIMS